Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/212584
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Aapro, Matti | - |
dc.contributor.author | Ruiz-Borrego, Manuel | - |
dc.contributor.author | Hegg, Roberto | - |
dc.contributor.author | Kukielka-Budny, Bozena | - |
dc.contributor.author | Morales, Serafin | - |
dc.contributor.author | Cinieri, Saverio | - |
dc.contributor.author | Freitas-Junior, Ruffo | - |
dc.contributor.author | García-Estévez, Laura | - |
dc.contributor.author | Szombara, Ewa | - |
dc.contributor.author | Santos Borges, Giuliano | - |
dc.contributor.author | Passalacqua, Rodolfo | - |
dc.contributor.author | Hervieu, Helene | - |
dc.contributor.author | Groc, Melanie | - |
dc.contributor.author | Villanova, Gustavo | - |
dc.date.accessioned | 2020-05-28T15:35:17Z | - |
dc.date.available | 2020-05-28T15:35:17Z | - |
dc.date.issued | 2019 | - |
dc.identifier | doi: 10.1016/j.breast.2019.01.009 | - |
dc.identifier | issn: 0960-9776 | - |
dc.identifier | e-issn: 1532-3080 | - |
dc.identifier.citation | Breast 45: 7-14 (2019) | - |
dc.identifier.uri | http://hdl.handle.net/10261/212584 | - |
dc.description.abstract | [Background] Single-agent paclitaxel and vinorelbine are recommended treatments for advanced breast cancer (ABC) non-responsive to hormone therapy and without visceral crisis. This phase II trial compared first-line oral vinorelbine versus weekly paclitaxel for ABC. [Methods] Eligible female patients had measurable locally recurrent/metastatic estrogen receptor-positive HER2-negative breast cancer and had received prior endocrine therapy (any setting) but no chemotherapy for ABC. Patients were stratified by prior taxane and visceral metastases and randomized to either oral vinorelbine 80 mg/m2 (first cycle at 60 mg/m2, escalated to 80 mg/m2 in the absence of grade 3/4 toxicity) or intravenous paclitaxel 80 mg/m2 on days 1, 8, and 15 every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR; confirmed complete or partial response, or stable disease for ≥6 weeks). [Results] The 131 randomized patients had received a median of 2 prior endocrine therapies; >70% had prior (neo)adjuvant chemotherapy and 79% visceral metastases. DCR was 75.8% (95% confidence interval: 63.6–85.5%) with vinorelbine and 75.4% (63.1–85.2%) with paclitaxel. The most common grade 3/4 adverse events were neutropenia (52%), fatigue (11%), and vomiting (5%) with vinorelbine, and neutropenia (17%), dyspnea (6%), hypertension (6%), and peripheral sensory neuropathy (5%) with paclitaxel. Grade 2 alopecia occurred in 2% of vinorelbine-treated and 34% of paclitaxel-treated patients. Neither arm showed relevant global health status changes. [Conclusion] Oral vinorelbine and paclitaxel demonstrated similar DCRs (∼75%). Safety profiles differed and, together with administration route and convenience, may influence treatment choice (EudraCT number, 2012-003530-16). | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.rights | closedAccess | - |
dc.subject | Oral chemotherapy | - |
dc.subject | Vinore | - |
dc.subject | lbine | - |
dc.subject | Weekly paclitaxel | - |
dc.subject | Breast | - |
dc.title | Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial) | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1016/j.breast.2019.01.009 | - |
dc.relation.publisherversion | https://doi.org/10.1016/j.breast.2019.01.009 | - |
dc.date.updated | 2020-05-28T15:35:17Z | - |
dc.relation.csic | Sí | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | artículo | - |
item.fulltext | No Fulltext | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
13
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
12
checked on 29-feb-2024
Page view(s)
125
checked on 25-abr-2024
Download(s)
11
checked on 25-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.